Navigation Links
Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
Date:5/14/2009

ROCKVILLE, Md., May 14 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that it will present posters on its newly approved atypical antipsychotic, Fanapt(TM) (iloperidone), at the 162nd American Psychiatric Association (APA) annual meeting in San Francisco, California. Fanapt(TM) is indicated for the acute treatment of schizophrenia in adults. Vanda will also present two posters on tasimelteon at APA. Tasimelteon is an investigational compound in development for the treatment of circadian rhythm sleep disorders, including transient insomnia caused by jet lag.

The following two posters discussing data from Fanapt(TM) clinical trials will be presented at scientific poster sessions on Monday, May 18 from 9:00 am to 10:30 am.

    NR1-033       Efficacy of Iloperidone is Comparable to Risperidone in
    Analyses of a Placebo- and Risperidone-Controlled Clinical Trial for
    Schizophrenia.

    NR1-026       The Comparative Efficacy of Iloperidone and Haloperidol
    Across Four Short-Term Controlled Trials.

The following four posters discussing genetic and genomic studies in schizophrenia will be presented at scientific poster sessions on Monday, May 18 from 9:00 am to 10:30 am (NR1-095, NR1-058, NR1-092) and on Wednesday, May 20 from 3:00 pm to 5:00 pm (NR7-009).

    NR1-095       Effect of 6 genetic markers associated with iloperidone
    efficacy on long term clinical outcome of patients who switch to
    iloperidone.

    NR1-058       Effect of polymorphisms in the dopamine receptor 2 gene on
    iloperidone efficacy for the treatment of patients with schizophrenia.

    NR7-009       Common effect of antipsychotics on biosynthesis and
    regulation of fatty acids and cholesterol supports a role of lipid
    homeostasis 
'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
2. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
3. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
4. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
5. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
6. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
7. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
8. Vanda Pharmaceuticals Reports First Quarter 2009 Results
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 2014 Research and Markets has ... Pulp & Paper Industry Report 2014" report to ... Pulp & Paper Industry Report 2014 is a professional ... global enzyme for pulp & paper industry. ... including definitions, classifications, applications and industry chain structure. The ...
(Date:8/27/2014)... Beach County, Florida (PRWEB) August 27, 2014 ... Company Inc. (SCI) is announcing the creation of ... priority is to take the SCI’s philosophy of ... the company’s research and development actions are based ... , This new Scientific Advisory Board provides a ...
(Date:8/27/2014)... August 27, 2014 Remcom announces an ... with new features for the biomedical industry. The ... Biological Thermal Sensor, exclusive to the Bio-Pro version of ... of XFdtd, developed to calculate the biological effects of ... been added to all versions to expand engineers’ post-processing ...
(Date:8/26/2014)...  NeuroSigma, Inc., a Los Angeles ... today announced that it has filed a registration statement ... Commission relating to a proposed initial public offering of ... offered and the price range for the proposed offering ... will act as the book-running manager for the proposed ...
Breaking Biology Technology:Global Enzyme for Pulp & Paper Industry Report 2014 2New Sancilio & Company, Inc. Scientific Board 2New Sancilio & Company, Inc. Scientific Board 3Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 2Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 3
... 28 N30 Pharma (N30), a,biopharmaceutical company focused ... regulate nitric oxide bioavailability,announced today that it has ... N30 will use proceeds from this financing ... expand its discovery and preclinical,research in the area ...
... Be Webcast Live On Company,s Website -, TUSTIN, ... ), a clinical stage biopharmaceutical,company developing monoclonal antibodies for ... that senior management will,present at the BIO Investor Forum ... (6:45 pm EDT). The conference will be held at ...
... ITMN ) announced today that it will release ... at 4:00 p.m. Eastern time.,A live conference call and ... time that same day., To access the live ... To access the,webcast, please log on to the company,s ...
Cached Biology Technology:N30 Pharma Announces Financing, Expansion of Board 2Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008 2InterMune to Release Third Quarter 2008 Financial Results on November 6 2
(Date:8/27/2014)... (June, 2014) Outstanding basic research, a growing ... dedication to patient care have earned the Herbert ... Medical Center (CUMC) and NewYork-Presbyterian Hospital an $18 ... National Cancer Institute (NCI). The grant renews the ... Comprehensive Cancer Centers in New York City and ...
(Date:8/27/2014)... factors thought to be associated with outcomes after ... age of the patient, mechanism of injury, nerve ... method, operation technique, and repair materials. However, despite ... peripheral nerve injuries, there is no agreement regarding ... the dose-effect relationship of the predictors has not ...
(Date:8/27/2014)... research finds , Gamblers show the same tendencies ... has shown. , Researchers, led by Dr Elliot Ludvig ... tests that found that both human gamblers and pigeons ... low-value rewards. , Published in Biology Letters , ... important role that memories of previous biggest wins and ...
Breaking Biology News(10 mins):Herbert Irving Comprehensive Cancer Center awarded $18 million grant 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 3Herbert Irving Comprehensive Cancer Center awarded $18 million grant 4Gamblers are greedy bird-brains, University of Warwick research finds 2
... the body's motor nerve cells grow along proper paths ... inhibiting spinal-cord neurons from regenerating after injury, researchers at ... the researchers found that a component of myelin ?a ... in adult vertebrates ?chemically blocks the ability of nerve ...
... for the first time that bacteria, in addition to ... sparkling wine known as Cava. They report their findings ... Society for Microbiology. , "Bacteria found in Cava samples ... in terms of aroma, flavor, bubble size and bubble ...
... hanging basket style device is at the heart of a plan ... sex drive of a major pest of fruit ... that very same pest. The device allows growers to selectively ... killing other beneficial insects. , The researchers at Warwick HRI, the ...
Cached Biology News:Researchers find molecule that inhibits regrowth of spinal nerve cells 2Researchers find molecule that inhibits regrowth of spinal nerve cells 3After the yeast is gone bacteria continue to develop flavor of sparkling wine 2Hanging baskets of sex and death help fruit growers 2